Back to Search Start Over

Real-world economic burden of hematopoietic cell transplantation among a large US commercially insured population with hematologic malignancies.

Authors :
Bonafede M
Richhariya A
Cai Q
Josephson NC
McMorrow D
Garfin PM
Perales MA
Source :
Journal of medical economics [J Med Econ] 2017 Dec; Vol. 20 (12), pp. 1244-1251. Date of Electronic Publication: 2017 Aug 24.
Publication Year :
2017

Abstract

Aims: Approximately 20,000 hematopoietic cell transplantation (HCT) procedures are performed in the US annually. This study aims to study the healthcare resource utilization and costs among commercially-insured patients with hematologic malignancies who received autologous HCT (auto-HCT) and allogeneic HCT (allo-HCT) in the US.<br />Materials and Methods: Adult patients with hematologic malignancies undergoing auto- or allo-HCT between January 1, 2011 and June 30, 2014 were identified in the Truven Health MarketScan Research Databases. Patients with 12 months of continuous pharmacy and medical enrollment pre- and post-HCT were included. Patients with prior HCT were excluded. Controls were selected from patients without any claims for HCT and matched with HCT recipients in a 3:1 ratio based on age, gender, insurance type, and Deyo-Charlson Comorbidity Index categories. Total healthcare resource uses and costs were compared between auto- or allo-HCT recipients and controls.<br />Results: In total, 10,527 patients (HCT, n = 2,672 vs control, n = 7,855) were included, with the majority of HCT recipients (63.6%) undergoing auto-HCT. During the 6-month pre-index and 12-month post-index period, auto-HCT recipients incurred $313,562 (p < .01) higher all-cause costs than controls, attributable to inpatient admission (54.1%), outpatient services (33.4%), and prescriptions (12.5%). The all-cause costs for allo-HCT recipients were $621,895 (p < .01) higher vs controls during the 18-month observation period, attributable to inpatient admissions (75.5%), outpatient services (22.1%), and prescriptions (2.4%).<br />Conclusions: The use of HCT among patients with hematologic malignancies is associated with considerable economic burden in direct healthcare costs in a commercially insured population. Incremental costs for HCT recipients were mainly driven by costs related to hospitalization and other medical services.

Details

Language :
English
ISSN :
1941-837X
Volume :
20
Issue :
12
Database :
MEDLINE
Journal :
Journal of medical economics
Publication Type :
Academic Journal
Accession number :
28782449
Full Text :
https://doi.org/10.1080/13696998.2017.1364648